RAQUEL
RIVERA DÍAZ
Profesora asociada de Ciencias de la Salud
Hospital Universitari Germans Trias i Pujol
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (62)
2024
-
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting
International Journal of Dermatology, Vol. 63, Núm. 4, pp. 503-511
-
Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain
Dermatologic Therapy, Vol. 2024
-
Improvements in the Management of Patients With Generalized Pustular Psoriasis in Spain: Recommendations From a Group of Experts
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 8, pp. 801-813
-
No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: Multicenter case series of 35 patients
Journal of the European Academy of Dermatology and Venereology
-
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice
Journal of the European Academy of Dermatology and Venereology, Vol. 38, Núm. 9, pp. 1783-1790
-
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study
Actas Dermo-Sifiliograficas
-
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry
British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363
2023
-
Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study
JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 488-501
-
Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population
Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326
-
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525
-
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345
-
Erythrodermic Psoriasis Has Become Less Frequent: Results From the Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. T366-T369
-
Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment
Dermatology and Therapy, Vol. 13, Núm. 3, pp. 673-688
-
Generalized pustular psoriasis: practical recommendations for Spanish primary care and emergency physicians
Postgraduate Medicine, Vol. 135, Núm. 8, pp. 766-774
-
High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting
International Journal of Dermatology
-
Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 10, pp. 865-883
-
Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 10, pp. 2004-2015
2022
-
Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry
British Journal of Dermatology
-
Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study
Dermatologic Therapy
-
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Dermatologic Therapy, Vol. 35, Núm. 2